Mechanism of action
Montelukast is a highly selective antagonist of the cysteinyl leukotriene receptor type 1 (CysLT1). Leukotrienes are inflammatory mediators produced by the 5-lipoxygenase pathway from arachidonic acid, primarily by mast cells, eosinophils, and basophils.
Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) bind to CysLT1 receptors in the airways, causing:
- Bronchoconstriction
- Increased vascular permeability and mucus secretion
- Eosinophil recruitment and activation
- Airway edema and remodeling
By competitively blocking CysLT1 receptors, montelukast prevents leukotriene-mediated effects. This reduces both the early and late-phase allergic response in asthma. Montelukast is particularly effective against aspirin-sensitive asthma and exercise-induced bronchoconstriction, conditions where leukotriene production is prominent.
Unlike bronchodilators, montelukast does not provide immediate relief but reduces background inflammation over days to weeks. It is an oral agent, providing a non-inhaled alternative for patients who struggle with inhaler technique.
- Montelukast is a CysLT1 receptor antagonist that blocks leukotriene-mediated bronchoconstriction and inflammation
- FDA black box warning for neuropsychiatric events: agitation, depression, suicidal ideation, vivid dreams
- Used for asthma maintenance (not acute attacks), allergic rhinitis, and exercise-induced bronchoconstriction prevention
- Particularly effective in aspirin-exacerbated respiratory disease (AERD) due to elevated leukotriene levels
- Eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss) can occur, especially during corticosteroid taper
- Chewable tablets contain phenylalanine; avoid in phenylketonuria patients
- Not a rescue medication; patients must have a short-acting beta-agonist for acute symptoms
- Metabolized by CYP2C8, CYP2C9, and CYP3A4; minimal clinically significant drug interactions
Indications
Asthma maintenance therapy: Montelukast is indicated for chronic treatment of asthma in adults and children. It is recommended as an alternative controller medication when inhaled corticosteroids are not tolerated or as add-on therapy in patients not adequately controlled on low-dose inhaled corticosteroids alone. It is not for acute asthma exacerbations or status asthmaticus.
Allergic rhinitis: Approved for seasonal and perennial allergic rhinitis in adults and children. It reduces nasal congestion, rhinorrhea, sneezing, and itching.
Exercise-induced bronchoconstriction (EIB): Montelukast prevents exercise-induced bronchoconstriction when taken prior to exercise. It should not be used in patients already taking montelukast daily for asthma or allergic rhinitis, as additional benefit is not established.
Aspirin-exacerbated respiratory disease (AERD): Though not formally approved, montelukast is commonly used in aspirin-sensitive asthma, as these patients have elevated leukotriene production.
Montelukast is not a rescue medication and should never replace short-acting beta-agonists for acute symptoms.
Pharmacokinetics
Absorption: Rapidly absorbed orally, with peak plasma concentrations reached in 3 to 4 hours for the tablet and 2 to 2.5 hours for the chewable tablet. Bioavailability of the tablet is approximately 64%.
Distribution: Highly protein-bound (greater than 99%), primarily to plasma proteins.
Metabolism: Extensively metabolized in the liver via cytochrome P450 enzymes, predominantly CYP2C8, CYP2C9, and CYP3A4. Montelukast undergoes first-pass metabolism.
Elimination: Excreted almost exclusively in bile; minimal renal excretion. The mean plasma half-life ranges from 2.7 to 5.5 hours in healthy adults. No dosage adjustment is required for renal impairment or mild-to-moderate hepatic impairment.
Special populations: Pharmacokinetics are similar across age groups when dosed appropriately. No dosage adjustment is needed in elderly patients or based on gender.
Adverse effects
Montelukast carries an FDA black box warning for serious neuropsychiatric events. Healthcare providers must inform patients and caregivers about these risks.
Neuropsychiatric effects (black box warning)
- Agitation, aggression, hostility
- Depression, suicidal thoughts and behavior
- Anxiety, sleep disturbances, vivid dreams, nightmares
- Hallucinations, disorientation, obsessive-compulsive symptoms
These events can occur at any time during treatment. The drug should be discontinued immediately if neuropsychiatric symptoms develop.
Common adverse effects
- Headache
- Upper respiratory infection
- Abdominal pain, diarrhea, nausea
- Pharyngitis
- Otitis media (in children)
Serious but rare adverse effects
- Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome): Rare systemic vasculitis associated with leukotriene receptor antagonists, particularly when oral corticosteroids are tapered. Presents with eosinophilia, vasculitic rash, pulmonary infiltrates, and cardiac or neurologic involvement.
- Hepatotoxicity: Elevated liver enzymes, cholestatic hepatitis (rare)
- Hypersensitivity reactions: Angioedema, urticaria, anaphylaxis (very rare)
Pediatric considerations
Children may be at higher risk for behavioral and mood changes. Parents should monitor for irritability, sleep problems, or behavioral changes.
Contraindications and warnings
Contraindications:
- Hypersensitivity to montelukast or any component of the formulation
Warnings:
- Neuropsychiatric events (black box warning): Monitor closely for mood or behavior changes. Discontinue if symptoms occur.
- Not for acute asthma: Montelukast is not a bronchodilator and should not be used to treat acute asthma attacks or status asthmaticus. Patients must have a rescue inhaler available.
- Systemic corticosteroid withdrawal: Do not abruptly substitute montelukast for inhaled or oral corticosteroids. EGPA has been reported during corticosteroid tapering.
- Aspirin sensitivity: While montelukast may help aspirin-sensitive asthma, patients should continue to avoid aspirin and NSAIDs unless undergoing desensitization.
- Phenylketonuria: Chewable tablets contain phenylalanine; counsel patients with PKU accordingly.
Pregnancy: Pregnancy category B. Animal studies show no harm, but human data are limited. Use only if clearly needed.
Lactation: Unknown if excreted in human milk; use caution in breastfeeding mothers.
Hepatic impairment: Use with caution in severe hepatic impairment, though no dosage adjustment is specified.
Drug interactions
Montelukast has relatively few clinically significant drug interactions due to its metabolism by multiple CYP pathways.
CYP450 inducers: Drugs that induce CYP2C8, CYP2C9, or CYP3A4 (e.g., phenobarbital, rifampin, carbamazepine) may decrease montelukast plasma concentrations, potentially reducing efficacy. The clinical significance is uncertain, and dose adjustment is not routinely recommended.
CYP450 inhibitors: Inhibitors of CYP2C8, CYP2C9, or CYP3A4 may theoretically increase montelukast levels, but clinically significant interactions are not well documented.
Gemfibrozil: This CYP2C8 and CYP2C9 inhibitor significantly increases montelukast plasma levels, but no dosage adjustment is recommended as the drug is generally well tolerated.
Other asthma medications: Montelukast can be safely combined with inhaled corticosteroids, long-acting beta-agonists, and short-acting beta-agonists. No significant pharmacokinetic interactions occur.
Warfarin: Rare case reports suggest potential for increased INR when montelukast is added to warfarin therapy. Monitor INR if initiating or discontinuing montelukast in anticoagulated patients.
No routine dose adjustments are required for drug interactions with montelukast.
Clinical pearls
- Aspirin-sensitive asthma: Montelukast is particularly effective in aspirin-exacerbated respiratory disease (AERD), where leukotriene overproduction drives symptoms. Consider this diagnosis in patients with asthma, nasal polyps, and aspirin sensitivity.
- Exercise-induced bronchoconstriction: When used solely for EIB prevention, montelukast should be taken at least 2 hours before exercise. If already on daily montelukast for asthma, taking an additional dose before exercise provides no added benefit.
- Steroid-sparing effect: Montelukast allows reduction of inhaled corticosteroid doses in some patients, but always taper steroids gradually to avoid precipitating EGPA.
- Churg-Strauss syndrome (EGPA): This rare vasculitis can occur when oral corticosteroids are tapered after starting montelukast. It is unclear whether montelukast causes EGPA or merely unmasks it by allowing corticosteroid reduction. Watch for eosinophilia, vasculitic rash, pulmonary infiltrates, or cardiac symptoms.
- Not a first-line controller: Current asthma guidelines recommend inhaled corticosteroids as first-line controller therapy. Montelukast is an alternative for patients who cannot or will not use inhalers, or as add-on therapy.
- Phenylketonuria: Chewable tablets contain aspartame (phenylalanine source); use film-coated tablets in PKU patients.
- Behavioral monitoring: Given the black box warning, document counseling about neuropsychiatric risks and encourage families to report mood or behavior changes promptly.
- Once-daily dosing: Typically dosed in the evening for asthma, though the optimal timing is debated. Evening dosing may align with circadian variation in asthma symptoms.
- No tachyphylaxis: Unlike some asthma medications, montelukast does not lose efficacy with long-term use.
LEUKOTRIENE: Leukotriene blocker, Evening dosing, Urokinase (not related, but EGPA can occur), Knockout CysLT1 receptors, Oral agent, Taper steroids cautiously, Rescue inhaler still needed, Irritability/mood changes (black box), Exercise-induced bronchoconstriction prevention, Neuropsychiatric effects, Eosinophilia in Churg-Strauss
Practice questions
1. A 9-year-old boy with asthma has been on low-dose inhaled corticosteroids for 6 months but continues to have symptoms 3-4 times per week. His mother reports he has nasal polyps and developed hives after taking ibuprofen for a headache last month. Which medication would be most appropriate to add to his regimen?
2. A 34-year-old woman with asthma on montelukast and inhaled corticosteroids presents to clinic with concerns about persistent rhinitis and a new rash on her legs. Laboratory studies show WBC 15,000/μL with 22% eosinophils. Chest X-ray reveals patchy infiltrates. What is the most likely diagnosis?
3. A 16-year-old competitive swimmer has been taking montelukast daily for persistent asthma for the past 3 months. She asks whether she should take an extra dose before swim practice to prevent exercise-induced symptoms. What is the most appropriate recommendation?
Frequently asked questions
How does montelukast work?
Montelukast works by blocking cysteinyl leukotriene receptors (CysLT1) in the airways. Leukotrienes are inflammatory chemicals that cause bronchoconstriction, mucus production, and airway swelling in asthma and allergies. By blocking these receptors, montelukast reduces inflammation and prevents bronchoconstriction over time. It is a maintenance medication that decreases background airway inflammation rather than providing immediate relief like a rescue inhaler.
What are the side effects of montelukast?
The most serious side effects are neuropsychiatric events including agitation, depression, anxiety, suicidal thoughts, vivid dreams, and behavioral changes, prompting an FDA black box warning. Common side effects include headache, upper respiratory infections, and abdominal pain. Rare but serious effects include eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), particularly when tapering corticosteroids, and liver enzyme elevations. Parents should monitor children closely for mood or behavior changes.
Is montelukast a steroid?
No, montelukast is not a steroid. It is a leukotriene receptor antagonist, a different class of anti-inflammatory medication. Unlike inhaled corticosteroids which broadly suppress airway inflammation, montelukast specifically blocks leukotriene receptors to reduce inflammation and bronchoconstriction. It is often used as an alternative to inhaled steroids in patients who cannot or will not use inhalers, or as add-on therapy when inhaled steroids alone do not adequately control asthma.
Can montelukast be used for acute asthma attacks?
No, montelukast cannot be used for acute asthma attacks or status asthmaticus. It is a maintenance medication that reduces background inflammation over days to weeks, not a bronchodilator that provides immediate relief. Patients must have a short-acting beta-agonist rescue inhaler (such as albuterol) available for acute symptoms. Using montelukast alone during an acute attack would be ineffective and dangerous. It should be continued during exacerbations alongside appropriate acute treatment.
Montelukast vs inhaled corticosteroids — what is the difference?
Inhaled corticosteroids (ICS) are first-line controller therapy for asthma and broadly suppress airway inflammation. Montelukast specifically blocks leukotriene receptors and is considered an alternative or add-on controller. ICS are generally more effective for most patients, but montelukast offers advantages including oral administration (no inhaler technique required), once-daily dosing, and effectiveness in aspirin-sensitive asthma. Current guidelines recommend ICS as preferred initial therapy, with montelukast reserved for patients who cannot use inhalers or need additional control.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: R03DC03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.